Zizzo Maurizio, Dorma Maria Pia Federica, Zanelli Magda, Sanguedolce Francesca, Bassi Maria Chiara, Palicelli Andrea, Ascani Stefano, Giunta Alessandro
Surgical Oncology Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.
Pathology Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.
Cancers (Basel). 2022 Jan 28;14(3):661. doi: 10.3390/cancers14030661.
Para-aortic lymph node (PALN) metastases represent patterns of initial recurrence in only 2-6% CRC patients, after an estimated 23-28 month time interval. An increasing trend towards curative surgery has been witnessed in patients presenting with controlled PALN recurrence. Nevertheless, lack of consensus has impaired an unambiguous statement for PALN recurrence resection.
We performed a systematic literature review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyzes (PRISMA) guidelines, which led us to gain deeper insight into the prognostic factors and long-term outcomes after resection for synchronous or metachronous pathologically confirmed CRC isolated para-aortic lymph node metastases (PALNM). Pubmed/MEDLINE, Embase, Scopus, Cochrane Library and Web of Science databases were used to search all related literature.
The nine articles included covered a study period of 30 years (1988-2018), with a total of 161 patients. At presentation, most primary CRCs were located in the colon (74%) and 95.6%, 87.1% and 76.9% patients had T3-T4, N1-N2 and well/moderately differentiated CRC, respectively. We identified a 59.4-68% 3-year OS rate and 53.4-87.5% 5-year OS rate, with a 25-84 months median OS, 26.3-61% 3-year DFS rate and 0-60.5% 5-year DFS rate, with a 14-24 month median DFS. Overall, 62.1% re-recurrence rate ranged from 43.8% to 100%.
Although PALNMs resection in CRC patients may be considered a feasible and beneficial option, no conclusions or recommendations can be made taking into account the current evidence. Therefore, further randomized, possibly multicenter trials are strongly recommended and mandatory if we want to have our results confirmed and patient selection criteria clearly identified.
腹主动脉旁淋巴结(PALN)转移仅占2%-6%的结直肠癌(CRC)患者初次复发模式,估计发生时间间隔为23-28个月。在出现可控的PALN复发的患者中,根治性手术的趋势日益明显。然而,缺乏共识阻碍了对PALN复发切除术的明确表述。
我们按照系统评价和荟萃分析的首选报告项目(PRISMA)指南进行了系统的文献综述,从而更深入地了解同步或异时性经病理证实的CRC孤立性腹主动脉旁淋巴结转移(PALNM)切除术后的预后因素和长期结局。使用Pubmed/MEDLINE、Embase、Scopus、Cochrane图书馆和科学网数据库搜索所有相关文献。
纳入的9篇文章涵盖30年(1988-2018年)的研究期,共161例患者。就诊时,大多数原发性CRC位于结肠(74%),95.6%、87.1%和76.9%的患者分别患有T3-T4、N1-N2和高/中分化CRC。我们确定3年总生存率为59.4%-68%,5年总生存率为53.4%-87.5%,中位总生存期为25-84个月,3年无病生存率为26.3%-61%,5年无病生存率为0%-60.5%,中位无病生存期为14-24个月。总体而言,62.1%的复发率在43.8%至100%之间。
尽管CRC患者的PALNM切除可能被认为是一种可行且有益的选择,但根据目前的证据无法得出结论或提出建议。因此,强烈建议进一步开展随机、可能多中心的试验,如果我们希望证实结果并明确患者选择标准,这是必不可少的。